Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Zentalis Pharmaceuticals stock

Own Zentalis Pharmaceuticals stock in just a few minutes.

Zentalis Pharmaceuticals, Inc is a biotechnology business based in the US. Zentalis Pharmaceuticals shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. Zentalis Pharmaceuticals employs 124 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Zentalis Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZNTL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Zentalis Pharmaceuticals share price

Use our graph to track the performance of ZNTL stocks over time.

Zentalis Pharmaceuticals shares at a glance

Information last updated 2021-04-23.
52-week range$25.41 - $61.29
50-day moving average $44.80
200-day moving average $44.55
Wall St. target price$66.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Zentalis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zentalis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zentalis Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -32.78%
Return on equity TTM -59.01%
Profit margin 0%
Book value N/A
Market capitalisation $2.4 billion

TTM: trailing 12 months

Shorting Zentalis Pharmaceuticals shares

There are currently 3.3 million Zentalis Pharmaceuticals shares held short by investors – that's known as Zentalis Pharmaceuticals's "short interest". This figure is 22.4% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Zentalis Pharmaceuticals shares can be evaluated.

Zentalis Pharmaceuticals's "short interest ratio" (SIR)

Zentalis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Zentalis Pharmaceuticals shares currently shorted divided by the average quantity of Zentalis Pharmaceuticals shares traded daily (recently around 282233.13609467). Zentalis Pharmaceuticals's SIR currently stands at 11.83. In other words for every 100,000 Zentalis Pharmaceuticals shares traded daily on the market, roughly 11830 shares are currently held short.

However Zentalis Pharmaceuticals's short interest can also be evaluated against the total number of Zentalis Pharmaceuticals shares, or, against the total number of tradable Zentalis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zentalis Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Zentalis Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.2016% of the tradable shares (for every 100,000 tradable Zentalis Pharmaceuticals shares, roughly 202 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Zentalis Pharmaceuticals.

Find out more about how you can short Zentalis Pharmaceuticals stock.

Zentalis Pharmaceuticals share dividends

We're not expecting Zentalis Pharmaceuticals to pay a dividend over the next 12 months.

Zentalis Pharmaceuticals overview

Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd. ; Pfizer, Inc. ; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site